LG Chem Successfully Concludes FAME Global 2024 Symposium on Global Fertility and Reproductive Medicine
■ Hosted Symposium for Over 130 Healthcare professionals from Eight Countries Including Vietnam, Thailand, and Mexico
■ Presented Latest Study Outcomes, Including RWE(Real World Evidence) on Ovulation Induction Brand Follitrope™ (follitropin)
■ Strategy to Expand Business from Infertility to Comprehensive Women’s Health to Support Women’s Treatment Journey
LG Chem has strengthened its presence by showcasing the achievements of its infertility treatment brands to a global audience.
LG Chem announced on the 8th that it successfully concluded the FAME (Fertility Advancement MEeting) Global symposium in Amsterdam, Netherlands, hosting over 130 healthcare professionals from eight countries, including Vietnam, Thailand, and Mexico, followed by the previous symposium in Milan, Italy in 2022.
During the symposium, four speakers from Asia and South America presented the latest research findings on the RWE(Real World Evidence) of the ovulation induction brand Follitrope™(follitropin) and shared insights on ART(assisted reproductive technologies) based on LG Chem products, emphasizing the unique competitiveness of LG Chem’s infertility treatment brands.
Furthermore, LG Chem presented its current fertility business status and strategy, highlighting its over 30-year brand heritage and remarkable global achievements. The Company is actively pioneering overseas markets with Follitrope™, the leading product in Korea’s fertility market. LG Chem announced that it is accelerating its market share growth in countries such as Vietnam, Mexico, and Thailand, where it has established itself as one of the leading brands. To achieve continual global success, the Company plans to enhance its healthcare professional academic marketing activities through medical expert advisory groups like the Global ABM (Advisory Board Meeting) and master courses such as WELG (World Expert ART Course by LG Chem).
In addition, LG Chem announced its strategy to expand its business scope beyond infertility to overall Women’s healthcare. This includes developing treatments for women’s diseases such as endometriosis and exploring the application of new medical technologies like digital therapeutics.
Heuisul Park, Senior Vice President and head of the Specialty Care business at LG Chem, stated, “We will enhance our academic programs to provide more effective treatment options to global healthcare professionals, thereby improving the success rate of infertility treatments. We are committed to expanding our business to comprehensively cover women’s diseases from reproductive age to old age, actively supporting the treatment journey of female patients.”
LG Chem launched Korea’s first recombinant follicle-stimulating hormone Follitrope™ in 2006, the highly purified menotropin IVF-M HP™ in 2013, and the premature ovulation inhibitor Ganilever™ in 2015, offering a diverse range of pharmaceutical options applicable across various assisted reproductive techniques.
At present, LG Chem exports and markets infertility treatment brands to about 20 countries, including Thailand, Vietnam, China, and Mexico, and plans to continue expanding its presence.
